The HP1BP3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human A-549 lung epithelial cell line, engineered to disrupt the HP1BP3 gene. This loss-of-function model enables systematic investigation of HP1BP3-dependent processes without small-molecule or RNAi approaches. The polyclonal format comprises a heterogeneous pool of edited cells, which can be employed for pooled functional assays or isolation of clones. By eliminating HP1BP3, researchers can dissect its contributions to chromatin dynamics, gene silencing, and genome integrity in a lung adenocarcinoma background.
The parental A-549 cell line was originally established from lung carcinoma tissue of a 58-year-old male and is widely used as a model for lung adenocarcinoma. These adherent epithelial cells retain features of alveolar type II pneumocytes, including surfactant protein expression, and exhibit robust growth in standard culture. A-549 cells harbor KRAS and STK11 mutations, driving oncogenic signaling and altered metabolism, making them particularly relevant for investigating epigenetic dysregulation in cancer. Their karyotype and transcriptional landscape provide a stable foundation for assessing functional impacts of HP1BP3 ablation on chromatin organization and DNA damage responses.
HP1BP3 functions as a histone chaperone that facilitates nucleosome assembly and interacts directly with the three HP1 homologs??CBX1, CBX3, and CBX5. These interactions mediate chromatin compaction and transcriptional silencing, anchoring HP1 proteins to genomic regions to establish repressive chromatin states. HP1BP3 also participates in DNA repair by modulating local chromatin architecture at damage sites, affecting recruitment of repair factors, and contributes to cell cycle progression through chromatin reorganization. Loss of HP1BP3 disrupts Histone H3 occupancy, impairs HP1-mediated gene silencing, and compromises chromatin remodeling, ultimately altering transcription and genome stability.
In the A-549 lung adenocarcinoma model, HP1BP3 knockout enables dissection of epigenetic regulation in oncogenic contexts. Lung adenocarcinoma progression features extensive chromatin reprogramming and DNA repair deficiencies, so ablating a chromatin organizer like HP1BP3 can reveal cancer-cell vulnerabilities. This model allows examination of how HP1BP3-dependent chromatin compaction influences expression of genes governing proliferation, epithelial-to-mesenchymal transition, and DNA damage tolerance. The known KRAS and STK11 mutations in A-549 provide a defined genetic background to study functional interactions between oncogenic signaling and HP1BP3-mediated chromatin control.
Researchers can employ these HP1BP3 Knockout A-549 Polyclonal Cells in diverse assays to probe chromatin biology and cancer epigenetics. Western blotting and immunofluorescence confirm HP1BP3 loss and assess HP1 localization. ChIP-qPCR or ChIP-seq reveal shifts in histone modifications and HP1 occupancy, while ATAC-seq captures chromatin accessibility changes. Co-immunoprecipitation tests HP1BP3-HP1 interactions, ??-H2AX foci assay measures DNA repair kinetics, and proliferation assays evaluate growth phenotypes. For technical specifications, contact Ascent Research.
